The relationship between statin use and breast cancer risk: NHANES 2003-2016 and Mendelian randomization study.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-18 DOI:10.1080/14737140.2025.2548488

Hao Shi, Ting Li, Yan Xu

{"title":"The relationship between statin use and breast cancer risk: NHANES 2003-2016 and Mendelian randomization study.","authors":"Hao Shi, Ting Li, Yan Xu","doi":"10.1080/14737140.2025.2548488","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is a prevalent malignancy, and statins are commonly used in the treatment of hyperlipidemia. However, the association between the use of statins and the risk of breast cancer is unclear. The aim of our study was to explore the relationship between statins and breast cancer risk by combining data analysis from the NHANES (National Health and Nutrition Examination Survey) and a Mendelian randomization (MR) study.Research design and methods: We collected and compiled data from the NHANES between 2003 and 2016. Logistic regression models were used to evaluate the associations between statin use and the risk of breast cancer. To further validate our findings, we selected two sets of instrumental variables and conducted a MR study. Additionally, we evaluated the robustness and reliability of the MR results through sensitivity analyses.Results: Based on the results of multivariate logistic regression analysis, statins may be a potential protective factor against breast cancer. For the MR analyses, inverse-variance weighted (IVW) analysis also revealed an association between exposure to statin-targeted inhibition and the risk of breast cancer.Conclusion: The administration of statins contributes to reduce the risk of breast cancer, which may open up new perspectives on breast cancer prevention.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2548488","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer is a prevalent malignancy, and statins are commonly used in the treatment of hyperlipidemia. However, the association between the use of statins and the risk of breast cancer is unclear. The aim of our study was to explore the relationship between statins and breast cancer risk by combining data analysis from the NHANES (National Health and Nutrition Examination Survey) and a Mendelian randomization (MR) study.

Research design and methods: We collected and compiled data from the NHANES between 2003 and 2016. Logistic regression models were used to evaluate the associations between statin use and the risk of breast cancer. To further validate our findings, we selected two sets of instrumental variables and conducted a MR study. Additionally, we evaluated the robustness and reliability of the MR results through sensitivity analyses.

Results: Based on the results of multivariate logistic regression analysis, statins may be a potential protective factor against breast cancer. For the MR analyses, inverse-variance weighted (IVW) analysis also revealed an association between exposure to statin-targeted inhibition and the risk of breast cancer.

Conclusion: The administration of statins contributes to reduce the risk of breast cancer, which may open up new perspectives on breast cancer prevention.

查看原文本刊更多论文

他汀类药物使用与乳腺癌风险的关系：NHANES 2003-2016和孟德尔随机研究。

背景：乳腺癌是一种常见的恶性肿瘤，他汀类药物常用于治疗高脂血症。然而，他汀类药物的使用与乳腺癌风险之间的关系尚不清楚。本研究的目的是通过结合NHANES（国家健康与营养调查）和孟德尔随机化（MR）研究的数据分析，探讨他汀类药物与乳腺癌风险之间的关系。研究设计与方法：我们收集并整理了2003 - 2016年NHANES的数据。Logistic回归模型用于评估他汀类药物使用与乳腺癌风险之间的关系。为了进一步验证我们的发现，我们选择了两组工具变量并进行了MR研究。此外，我们通过敏感性分析评估MR结果的稳健性和可靠性。结果：多因素logistic回归分析结果显示，他汀类药物可能是乳腺癌的潜在保护因素。对于MR分析，逆方差加权（IVW）分析也揭示了他汀类药物靶向抑制暴露与乳腺癌风险之间的关联。结论：他汀类药物的应用有助于降低乳腺癌的发生风险，为乳腺癌的防治开辟了新的思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.